Trial purpose
Cancer treatment
Tumor type
Gynaecological
Age
18+
Clinical summary
Summary
This study has two parts. Part 1 is investigating the safety of the combination of ATX-101 with carboplatin/pegylated liposomal doxorubicin (ACD). ATX-101 will be administered intravenously in three escalation cohorts: 20, 30, and 45 mg/m² according to a 3+3 design. In the case where 20 mg/m² is not tolerated, the dose can be de-escalated to 15 mg/m². Pegylated liposomal doxorubicin (30 mg/m²) will be administered intravenously on Day 1 of each 28-day cycle; carboplatin (AUC5) will be administered intravenously on Day 1 of each cycle. Part 2 will be further investigating the efficacy and safety of this combination. In this part, ATX-101 will be administered at the dose defined in part 1 of the study.
Conditions
This trial is treating people with platinum-sensitive, recurrent ovarian, fallopian tube or primary peritoneal cancer
Eligibility
Inclusion
- Women ≥ 18 years of age
-
Is not a woman of childbearing potential:
- Surgically sterile (i.e., had a bilateral tubal ligation, hysterectomy, salpingectomy, or bilateral oophorectomy at least 6 months prior to Day 1 of the study) or;
- Postmenopausal for at least 1 year prior to Day 1 of the study, and have follicle stimulating hormone levels in the postmenopausal range for the study site.
- Signed written informed consent
- Histologically confirmed high grade serous or endometrioid carcinoma of the ovary, fallopian tube, or primary peritoneal cancer
- 1 to 3 prior systemic treatment lines. Prior maintenance therapy with bevacizumab or PARP inhibitors is permitted.
- Platinum-sensitive carcinoma, defined as disease progression after ≥ 6 months following the most recent platinum-based therapy of the disease
- Measurable disease on CT/MRI scan according to RECIST 1.1
- ECOG Performance status 0 to 1
- Life expectancy of at least 6 months
-
Meet the following laboratory requirements:
- Hemoglobin (HGB) ≥ 100 × 109/L
- Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
- Platelet count ≥ 100 × 109/L
- aPTT/PT ≤ 1.5 x ULN
- Total bilirubin level ≤ 1.5 × ULN
- AST and ALT ≤ 2.5 × ULN (≤ 5 × ULN if liver metastasis present)
- Creatinine Clearance > 60 mL/min, as calculated by Cockcroft-Gault formula, or serum creatinine ≤ 1.5 × ULN.
Exclusion
- Have received an anti-cancer/investigational drug within 4 weeks prior to study drug administration
- Have received a vaccine for COVID-19 within 14 days prior to the first dose of ATX-101 or are scheduled/intend to have a COVID-19 vaccine on Day 1 or during the DLT period (i.e. C1D2 [Day 2] through to C2D2 [Day 30]) of the study
- Have not recovered from AEs (≥ CTCAE Grade 2 other than alopecia) due to agent(s) administered more than 4 weeks earlier
- Radiotherapy within 4 weeks prior to study drug administration
- Major surgery or significant trauma within 28 days (4 weeks) of Screening
- Anticipated requirement for surgery or initiation of anti-cancer therapy, other than described in this study protocol, during the study period
- Known hypersensitivity to any of the combination partners of ATX-101
- Any malignancy over the last 5 years, other than ovarian/fallopian tube/primary peritoneal cancer, with exception of basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that is considered cured by excision
- Cardiac failure NYHA III/IV.
- LVEF < 50% (ECHO or MUGA must not be older than 12 weeks)
- QTcF > 470 msec
- Any organ dysfunction or current acute or chronic disease, other than the study indication, that would significantly increase the expected risk in participants participating in the study, in the judgment of the Investigator
- Pregnant or breast-feeding women
- Unwilling or unable to follow protocol requirements
- A past positive status of HIV and/or positive for HIV at Screening
- Active Hepatitis B or C. In participants with a history of Hepatitis B or Hepatitis C infection, HBsAg and HCV RNA tests have to be negative.
Inclusion
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back (relapsed or recurrent).
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
THERAPIM PTY LTD
Scientific Title
Phase 1b/2a Study Investigating ATX-101 in Combination With Platinum-based Chemotherapy in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information